Al B. Benson, MD, discusses recent developments for the treatment of patient with hepatocellular carcinoma with systemic therapy in the first and second line.
Al B. Benson, MD, professor of Medicine, Hematology and Oncology, Northwestern University Feinberg School of Medicine, discusses recent developments for the treatment of patient with hepatocellular carcinoma (HCC) with systemic therapy in the first and second line.
Benson says it’s important to determine when a patient with HCC would do best with a systemic therapy rather than a liver-targeted therapy. Recently, there have been many advances in this setting. Patients used to only have single-agent sorafenib (Nexavar) as an option, but now there are multiple kinds of approaches in the first and second line. This includes lenvatinib (Lenvima) in the first line and regorafenib (Stivargo), nivolumab (Opdivo), pembrolizumab (Keytruda), and cabozantinib (Cabometyx) as second-line therapies.
Additionally, immunotherapy has become a topic of interest for these patients according to Benson. The combination of atezolizumab (Tecentriq) plus bevacizumab (Avastin) is now FDA-approved as a treatment for patients with unresectable or metastatic HCC who have not received systemic therapy before. This was based on the IMbrave150 trial (NCT03434379).
Phase 3 VERIFY Trial Investigates Rusfertide’s Potential in Polycythemia Vera
July 16th 2024In an interview, Aniket Bankar, MD, discussed the background, design, and goals of the phase 3 VERIFY trial of the hepcidin mimetic rusfertide for the treatment of patients with polycythemia vera.
Read More
Examining Breast Cancer Recurrence Detection Methods in a Community Oncology Setting
July 12th 2024In an interview with Targeted Oncology, Ali Duffens, MD, discussed findings from a study which investigated detecting breast cancer recurrence among women treated at Kaiser Permanente Northern California.
Read More